menu
    • menu
    [{"orgOrder":0,"company":"Fresenius Kabi AG","sponsor":"CSL Vifor","pharmaFlowCategory":"D","upfrontCash":"Undisclosed","therapeuticArea":"Hematology","country":"GERMANY","productType":"Small molecule","date":"February 2020","year":"2020","type":"Partnership","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Fresenius Kabi AG","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Fresenius Kabi AG \/ Vifor Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Fresenius Kabi AG \/ Vifor Pharma"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"September 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Cardiology\/Vascular Diseases","country":"","productType":"Small molecule","date":"November 2020","year":"2020","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Cardiology\/Vascular Diseases","graph2":"Phase IV","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Cardiovascular Diseases","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"11","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"M.D. Anderson Cancer Center","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2021","year":"2021","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Intravenous Injection","sponsorNew":"Daiichi Sankyo \/ M.D. Anderson Cancer Center","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ M.D. Anderson Cancer Center"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","upfrontCash":"$11,700.0 million","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"December 2021","year":"2021","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":11.699999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":11.699999999999999,"dosageForm":"Intravenous Infusion","sponsorNew":"CSL Vifor \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ CSL"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"November 2022","year":"2022","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"Emcure Pharmaceuticals","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"May 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Emcure Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Emcure Pharmaceuticals \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"Emcure Pharmaceuticals \/ Not Applicable"},{"orgOrder":0,"company":"Daiichi Sankyo","sponsor":"American Regent","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"June 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"Daiichi Sankyo","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"Daiichi Sankyo \/ American Regent","highestDevelopmentStatusID":"12","companyTruncated":"Daiichi Sankyo \/ American Regent"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"CSL","pharmaFlowCategory":"D","upfrontCash":"$11,700.0 million","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2022","year":"2022","type":"Acquisition","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":11.699999999999999,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":11.699999999999999,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ CSL","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ CSL"},{"orgOrder":0,"company":"American Regent","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"American Regent","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"American Regent \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"American Regent \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"August 2023","year":"2023","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Injectable\/Injection","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"},{"orgOrder":0,"company":"CSL Vifor","sponsor":"Not Applicable","pharmaFlowCategory":"DU","upfrontCash":"Not Applicable","therapeuticArea":"Hematology","country":"","productType":"Small molecule","date":"March 2024","year":"2024","type":"Not Applicable","leadProduct":"Ferric Carboxymaltose","moa":"","graph1":"Hematology","graph2":"Approved","graph3":"CSL Vifor","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"CSL Vifor \/ Not Applicable","highestDevelopmentStatusID":"12","companyTruncated":"CSL Vifor \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Ferric Carboxymaltose

    Menu

    Ferric Carboxymaltose

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ferinject® Approved by Health Canada for Iron Deficiency Anemia in Adults and Pediatrics

                            Details : Ferinject (ferric carboxymaltose) is an approved small molecule Fe modulator for treating iron deficiency anemia in patients aged one year and older when oral iron is not tolerated.

                            Brand Name : Ferinject

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            March 19, 2024

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ferinject® Granted Upgraded Recommendations in 2023 ESC Heart Failure Guidelines

                            Details : Ferinject (ferric carboxymaltose) is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen around...

                            Brand Name : Ferinject

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 28, 2023

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            American Regent

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed

                            American Regent

                            U.S.A arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            American Regent Announces Results From Phase 3 HEART-FID Trial with INJECTAFER®

                            Details : Injectafer (ferric carboxymaltose injection) is indicated for the improvement of exercise capacity for iron deficient adult patients with symptomatic heart failure; iron deficiency anemia (IDA) in adult and pediatric patients 1 year of age and older.

                            Brand Name : Injectafer

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            August 26, 2023

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Daiichi Sankyo

                            Japan arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : American Regent

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            INJECTAFER Approved in the U.S. for the Treatment of Iron Deficiency in Adult Patients with Heart Failure

                            Details : Injectafer (ferric carboxymaltose injection) is indicated for the treatment of iron deficiency in adult patients with iron deficiency in adult patients with heart failure categorized.

                            Brand Name : Injectafer

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            June 05, 2023

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : American Regent

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Emcure Pharmaceuticals

                            India arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Emcure Pharmaceuticals

                            India arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Emcure Pharmaceuticals to Launch The 750 Mg Injectable Variant of Ferric Carboxymaltose

                            Details : Orofer (ferric carboxymaltose) which is capable of releasing iron, helping in the synthesis of haemoglobin and increases red blood cell count. As a result, it treats iron deficiency anaemia.

                            Brand Name : Orofer

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 17, 2023

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Ferinject® Approved In Chinafor The Treatment Of Iron Deficiency In Adult Patients

                            Details : Ferinject 50mg/ml Solution for Injection is an iron replacement medicine, used to treat a type of anemia where you have fewer amount of red blood cells due to insufficient iron in your body. Iron is needed to produce the red blood cells that carry oxygen...

                            Brand Name : Ferinject

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 28, 2022

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : CSL

                            Deal Size : $11,700.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Finalization of Vifor Pharma Acquisition

                            Details : CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).

                            Brand Name : Ferinject

                            Molecule Type : Small molecule

                            Upfront Cash : $11,700.0 million

                            August 02, 2022

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : CSL

                            Deal Size : $11,700.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : CSL

                            Deal Size : $11,700.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            CSL Limited Announces Tender Offer to Acquire Vifor Pharma Ltd

                            Details : CSL Limited acquire Vifor Pharma's therapeutic segment of iron deficiency, nephrology and cardio-renal therapies containing Venofer® and Maltofer® and strategic growth driver Ferinject®/Injectafer® (ferric carboxymaltose).

                            Brand Name : Ferinject

                            Molecule Type : Small molecule

                            Upfront Cash : $11,700.0 million

                            December 14, 2021

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : CSL

                            Deal Size : $11,700.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Daiichi Sankyo

                            Japan arrow
                            Aquaexpo 2024
                            Not Confirmed

                            Daiichi Sankyo

                            Japan arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Study Phase : Approved

                            Sponsor : M.D. Anderson Cancer Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Daiichi Sankyo's Injectafer® Receives FDA Approval for Single Dose Option for the Treatment of Adult Patients...

                            Details : The U.S FDA has approved a single 1000 mg dose option of Injectafer®, ferric carboxymaltose injection, an iron replacement product, for iron deficiency anemia patients who have intolerance to oral iron, have low response to oral iron, or have non-dialys...

                            Brand Name : Injectafer

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            May 06, 2021

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Hematology

                            Highest Development Status : Approved

                            Sponsor : M.D. Anderson Cancer Center

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed

                            CSL Vifor

                            Switzerland arrow
                            Aquaexpo 2024
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Study Phase : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Vifor Pharma's AFFIRM-AHF Study Show Ferinject® Reduces Hospitalizations After Acute Heart Failure in Patient...

                            Details : The study demonstrated there were significantly fewer hospital readmissions due to HF among patients treated with Ferinject® compared to placebo.

                            Brand Name : Ferinject

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            November 13, 2020

                            Lead Product(s) : Ferric Carboxymaltose

                            Therapeutic Area : Cardiology/Vascular Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth